Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An announcement from Neurocrine ( (NBIX) ) is now available.
On January 24, 2025, Neurocrine Biosciences announced an amendment to its Exclusive License Agreement with Takeda Pharmaceutical, originally established in June 2020, to develop and commercialize osavampator. The amended agreement allows Neurocrine exclusive rights to develop and commercialize osavampator worldwide, except in Japan where Takeda retains rights. This strategic move shifts the partnership to a royalty-bearing license, positioning Neurocrine to advance osavampator, a potential first-in-class AMPA modulator for major depressive disorder, into Phase 3 trials. The agreement outlines shared development costs and mutual royalty arrangements, potentially enhancing Neurocrine’s market positioning and stakeholder value by streamlining its focus on osavampator’s global development, excluding Japan.
More about Neurocrine
Neurocrine Biosciences is a neuroscience-focused biopharmaceutical company dedicated to developing treatments for neurological, neuroendocrine, and neuropsychiatric disorders. Their portfolio includes FDA-approved treatments for conditions such as tardive dyskinesia and Huntington’s disease, along with a robust pipeline of compounds in various stages of clinical development.
YTD Price Performance: 7.88%
Average Trading Volume: 1,005,289
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $15.06B
For an in-depth examination of NBIX stock, go to TipRanks’ Stock Analysis page.
